Marker Therapeut Stock Price, News & Analysis

Marker Therapeutics, Inc. (Nasdaq: MRKR) announced the presentation of four posters on its Multi-Tumor-Associated Antigen (MultiTAA)-specific T cell therapies at the 2022 ISCT Annual Meeting in San Francisco from May 4-7, 2022. CEO Peter L. Hoang highlighted improvements in manufacturing processes leading to faster production and enhanced potency, particularly for MT-401 in Phase 2 trials for post-transplant AML. The posters will cover topics including the clinical results from the Phase 2 AML trial and advances in T cell manufacturing technology.

Marker Therapeutics (MRKR) announced a services agreement with Wilson Wolf Manufacturing, featuring an $8 million upfront payment and a potential additional $1 million. This partnership highlights Marker’s expertise in cell therapy manufacturing, allowing it to maintain control and reduce costs. CEO Peter Hoang emphasized the benefits of having in-house production capabilities. The deal is expected to enhance Marker’s operations, particularly in treating hematological and solid tumors, while showcasing Wilson Wolf's confidence in Marker’s technology.

Marker Therapeutics, Inc. (Nasdaq:MRKR) reports completion of patient enrollment in its Phase 2 AML trial for lead product MT-401, with a topline readout anticipated in Q2 2022. The company has developed a new nine-day manufacturing process for T cell therapies, increasing potency and reducing production time. Additionally, plans are in place to file INDs for lymphoma and pancreatic cancer by the end of 2022. However, in 2021, Marker reported a net loss of $41.9 million and increased R&D expenses of $27.8 million, compared to $18.9 million in 2020.

Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology firm, announced that CFO Anthony H. Kim will present at two investor conferences in March 2022. The first is the ROTH Annual Conference on March 14 at 11:00 a.m. ET, followed by the Oppenheimer Virtual Annual Healthcare Conference on March 17 at 10:40 a.m. ET. Webcasts of both presentations will be available on the company's website. Marker is focused on developing non-engineered, tumor-specific T cell therapies for hematological malignancies and solid tumors.

Marker Therapeutics (MRKR) reported positive outcomes from the safety lead-in stage of its Phase 2 AML trial, with no severe adverse effects and one MRD positive patient achieving MRD negativity after treatment with MT-401. The company has developed a new T cell manufacturing process, reducing production time to nine days and enhancing product potency and specificity. Plans include expanding their pipeline into solid tumors like pancreatic cancer, with additional IND filings expected by year-end 2022. A conference call will be held today to discuss these developments further.

Marker Therapeutics, Inc. (Nasdaq:MRKR) announced a conference call and webcast on February 16, 2022, at 5:00 p.m. EST to discuss updates on its clinical programs and pipeline. The event will be accessible via the Investors section of the company's website. Marker specializes in next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, focusing on non-engineered, tumor-specific T cells. The company believes its therapies are easier to manufacture and less toxic than current CAR-T and TCR approaches, potentially providing significant clinical benefits.

Marker Therapeutics (NASDAQ:MRKR) announced that the FDA has granted Orphan Drug designation to MT-601, a T cell product targeting pancreatic cancer. The designation highlights MT-601’s potential to treat a disease with a low 5-year survival rate. The product targets multiple tumor-associated antigens and is in a Phase 1 trial showing promising results. The company plans to initiate a multicenter study combining MT-601 with chemotherapy and file an Investigational New Drug Application in 2022. Orphan designation may provide various benefits, including market exclusivity.

Marker Therapeutics (NASDAQ: MRKR) has appointed Dr. Katharine Knobil to its Board of Directors, bringing over 20 years of leadership in clinical development, notably at GlaxoSmithKline. This strategic move is expected to enhance Marker’s capabilities as it develops novel T cell therapies for cancer treatment. Dr. Knobil currently serves as Chief Medical Officer at Agilent Technologies and holds prior roles at Kaleido Biosciences. Her expertise may contribute significantly as Marker Therapeutics advances its immunotherapy initiatives.

Marker Therapeutics (NASDAQ: MRKR) announced that data from its Phase 1 study on MultiTAA-specific T cells will be presented at the 2021 ASH Annual Meeting, set for December 11-14 in Atlanta and virtually. The oral presentation, titled "Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL," will occur on December 12 at 12:30 p.m. ET. The study, conducted in partnership with Baylor College of Medicine, showcases Marker's innovative approach to T cell-based immunotherapies for hematological malignancies.